|
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive
based on the application of the treasury stock method and because the Company incurred net losses during the period:
SCHEDULE
OF ANTI DILUTIVE SECURITIES
| |
|
2023 |
|
|
2022 |
|
| |
|
For the Three Months Ended March 31, |
|
| |
|
2023 |
|
|
2022 |
|
| Convertible notes payable |
|
|
18,194,940 |
|
|
|
5,929,940 |
|
| Warrants to purchase shares of common stock |
|
|
12,578,478 |
|
|
|
8,432,558 |
|
| Total potentially dilutive shares |
|
|
30,773,418 |
|
|
|
14,362,498 |
|
|